GlassScriptPhysician profile
Jennifer J Lee
NPI 1548478936
$395,783.52
in general payments reported to CMS, 2019-2025
30 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $813 · 2021: $2,079 · 2022: $66K · 2023: $109K · 2024: $87K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250K · Consulting Fee: $28K · Travel and Lodging: $24K · Food and Beverage: $6,993 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250,206.00 |
| Consulting Fee | $27,880.00 |
| Travel and Lodging | $23,604.04 |
| Food and Beverage | $6,992.60 |
| Education | $254.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305,884.84 | 2019-2025 | |
| Allergan, INC. | $66,177.66 | 2019-2022 | |
| Merz North America, INC. | $14,219.83 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $5,366.22 | 2019-2025 | Dysport, Nemluvio |
| Janssen Biotech, INC. | $942.16 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $598.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $362.31 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $281.26 | 2019-2024 | Ilumya, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $243.32 | 2019-2025 | Sotyktu |
| Genzyme Corporation | $217.28 | 2020-2025 | |
| Ucb, INC. | $203.00 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $194.82 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $188.72 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $125.20 | 2022-2025 | |
| Incyte Corporation | $123.42 | 2023-2025 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.72 | 2022-2025 | Arazlo, Jublia, Cabtreo |
| Almirall LLC | $84.22 | 2023-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $80.83 | 2019-2022 | |
| Dermavant Sciences, INC. | $59.77 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $44.75 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $42.30 | 2019-2025 | Adbry |
| Journey Medical Corporation | $41.18 | 2022 | |
| Botanix Sb INC | $40.37 | 2025 | Sofdra |
| Novo Nordisk INC | $28.08 | 2025 | Rybelsus, Ozempic |
| Mallinckrodt Hospital Products INC. | $26.95 | 2025 | Acthar |
| Biofrontera INC. | $24.71 | 2025 | |
| Lnhc, INC | $20.55 | 2025 | Zelsuvmi |
| Organon LLC | $20.47 | 2025 | |
| Genentech USA, INC. | $17.65 | 2019 | |
| Dermira, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.